Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial

被引：17
|
作者：
Katsiki, Niki [1 ]
Athyros, Vasilios G. [1 ]
Mikhailidis, Dimitri P. [2 ]
Mantzoros, Christos [3 ]
机构：
[1] Aristotle Univ Thessaloniki, Hippocrat Hosp, Med Sch, Propedeut Dept Internal Med 2, Thessaloniki, Greece
[2] UCL, Royal Free Hosp Campus, Med Sch, Dept Clin Biochem, London, England
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Internal Med, Div Endocrinol Diabet & Metab, Boston, MA USA
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2017年 / 74卷
关键词：
GENETIC-VARIANTS; REDUCING LIPIDS; STATIN THERAPY; MANAGEMENT; EVOLOCUMAB; EFFICACY; SAFETY; DYSLIPIDEMIA; ASSOCIATION; ALIROCUMAB;
D O I：
10.1016/j.metabol.2017.04.007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：43 / 46
页数：4
相关论文
共 50 条
  • [21] Modulation of the Vascular Endothelial Inflammatory Response by Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9)
    Leung, A. K.
    Grzelkovski, G.
    Roveran Genga, K.
    Russell, J. A.
    Boyd, J. H.
    Walley, K. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [22] Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse
    Saeed, Anum
    Virani, Salim S.
    Jones, Peter H.
    Ballantyne, Christie M.
    Nambi, Vijay
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (05) : 1141 - 1145
  • [23] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in dialysis patients
    Torino, Claudia
    Carbone, Federico
    Pizzini, Patrizia
    Mezzatesta, Sabrina
    D'Arrigo, Graziella
    Gori, Mercedes
    Liberale, Luca
    Moriero, Margherita
    Michelauz, Cristina
    Fre, Federica
    Isoppo, Simone
    Gavoci, Aurora
    La Rosa, Federica
    Scuricini, Alessandro
    Tirandi, Amedeo
    Ramoni, Davide
    Mallamaci, Francesca
    Tripepi, Giovanni
    Montecucco, Fabrizio
    Zoccali, Carmine
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2024, 54 (09)
  • [24] Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in diabetic complications
    Imaralu, Omonzejie E.
    Narasimhulu, Chandrakala Aluganti
    Singal, Pawan K.
    Singla, Dinender K.
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2024, 102 (01) : 14 - 25
  • [25] Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
    Rainer Schulz
    Klaus-Dieter Schlüter
    Ulrich Laufs
    Basic Research in Cardiology, 2015, 110
  • [26] Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
    Schulz, Rainer
    Schlueter, Klaus-Dieter
    Laufs, Ulrich
    BASIC RESEARCH IN CARDIOLOGY, 2015, 110 (02)
  • [27] Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
    Bell, Andrew S.
    Wagner, Josephin
    Rosoff, Daniel B.
    Lohoff, Falk W.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2023, 149
  • [28] Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) Insights From the Department of Veterans Affairs
    Virani, Salim S.
    Akeroyd, Julia M.
    Nambi, Vijay
    Heidenreich, Paul A.
    Morris, Pamela B.
    Nasir, Khurram
    Michos, Erin D.
    Bittner, Vera A.
    Petersen, Laura A.
    Ballantyne, Christie M.
    CIRCULATION, 2017, 135 (25) : 2572 - 2574
  • [29] IDENTIFICATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FROM NATURAL PRODUCTS
    Hirata, Hiroshi
    Kontani, Ami
    Takazumi, Koji
    Segawa, Shuichi
    Tsuchiya, Youichi
    ANNALS OF NUTRITION AND METABOLISM, 2017, 71 : 1175 - 1175
  • [30] Managed Care Pharmacist Updates for Proprotein Convertase Subtilisin/kexin type 9 (PCSK9) Inhibitors
    Patel, Jeenal
    AMERICAN JOURNAL OF MANAGED CARE, 2021, 27 (04): : S76 - S82
12345